Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
Status:
Completed
Trial end date:
2014-06-09
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal
adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies. The
purpose of this study is to assess the safety (including the recommended phase 2 dose), the
pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063).